This post was originally published on this site
Biomarin Pharma announced earnings per share of $-0.2 on revenue of $408.7M. Analysts polled by Investing.com anticipated EPS of $-0.2427 on revenue of $435.89M.
Biomarin Pharma shares are down 18.21% from the beginning of the year, still down 22.51% from its 52 week high of $92.55 set on December 17, 2020. They are under-performing the Nasdaq which is up 18.21% from the start of the year.
Biomarin Pharma shares lost 0.31% in after-hours trade following the report.
Biomarin Pharma’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
